FT819 is named as an intervention in 3 current clinical trials in our USA and UK registers. 2 are recruiting patients now. The most common phase is Phase 1. The lead sponsor is Fate Therapeutics. The most-studied condition is Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV).
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
NCT07570862 · ClinicalTrials.gov ↗ · Lupus Nephritis, Systemic Lupus Erythematosus, SLE - Systemic Lupus Erythematosus
|
Phase 2 | Recruiting | Fate Therapeutics | USA |
|
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
NCT06308978 · ClinicalTrials.gov ↗ · Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc)
|
Phase 1 | Recruiting | Fate Therapeutics | UK, USA |
|
FT819 in Subjects With B-cell Malignancies
NCT04629729 · ClinicalTrials.gov ↗ · Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia
|
Phase 1 | Active, closed | Fate Therapeutics | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Fate Therapeutics | 3 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 3 | 2 |
| Clinical trials in UK | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our USA and UK registers name FT819 as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 3 trials are recruiting: 2 with sites in USA and 1 with sites in UK. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Fate Therapeutics. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how FT819 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how FT819 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists FT819 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.